WO2006095764A1 - Agent for suppressing uv sensitivity in skin and functional beverage and food - Google Patents

Agent for suppressing uv sensitivity in skin and functional beverage and food Download PDF

Info

Publication number
WO2006095764A1
WO2006095764A1 PCT/JP2006/304453 JP2006304453W WO2006095764A1 WO 2006095764 A1 WO2006095764 A1 WO 2006095764A1 JP 2006304453 W JP2006304453 W JP 2006304453W WO 2006095764 A1 WO2006095764 A1 WO 2006095764A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
sensitivity
ultraviolet
fermented milk
suppressing
Prior art date
Application number
PCT/JP2006/304453
Other languages
French (fr)
Japanese (ja)
Inventor
Chiaki Yoshimura
Akihiro Masuyama
Hidehiko Baba
Original Assignee
Calpis Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calpis Co., Ltd. filed Critical Calpis Co., Ltd.
Priority to JP2007507144A priority Critical patent/JPWO2006095764A1/en
Publication of WO2006095764A1 publication Critical patent/WO2006095764A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20Milk; Whey; Colostrum
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52Adding ingredients
    • A23L2/66Proteins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/19Dairy proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/18Antioxidants, e.g. antiradicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

[PROBLEMS] To provide an agent for suppressing the sensitivity to UV radiation which, when taken through oral administration, can exhibit an effect of suppressing the sensitivity to UV radiation in the skin, including an effect of inhibiting the development of erythema caused by UV radiation and an effect of suppressing the skin tanning associated with the erythema; and a beverage or food comprising the agent. [MEANS FOR SOLVING PROBLEMS] The agent for suppressing the sensitivity to UV radiation comprises a fermented milk whey which can be produced by fermenting a milk by Lactobacillus helveticus as the active ingredient. The functional beverage or food comprises the agent and is characterized by having an effect of suppressing the sensitivity to UV radiation in the skin, including an effect of inhibiting the development of erythema and an effect of suppressing the skin tanning associated with the erythema.

Description

明 細 書  Specification
皮膚における紫外線感受性抑制剤及び機能性飲食品  UV sensitivity inhibitor and functional food and drink in skin
技術分野  Technical field
[0001] 本発明は、紫外線による、皮膚紅斑発症抑制作用、該紅斑に伴う皮膚黒化抑制作 用等の皮膚における紫外線感受性抑制作用を有する経口摂取用の剤及び該剤を 含む機能性飲食品に関する。  [0001] The present invention relates to an orally ingesting agent having an action of inhibiting the development of skin erythema caused by ultraviolet rays, an effect of inhibiting the sensitivity of skin to ultraviolet rays such as the action of inhibiting skin darkening associated with the erythema, and a functional food or drink containing the agent About.
背景技術  Background art
[0002] 発酵乳ゃホエー等の乳酸菌発酵代謝物、乳酸菌の菌体外又は菌体内産生物は、 その菌種ゃ発酵条件等の相違に応じて、健康に対して有用な様々な機能を有する 場合があることが見出されている。例えば、特定の発酵代謝物中、若しくは菌体外又 は菌体内産生物中に、整腸作用、抗腫瘍作用、高血圧抑制作用、抗アレルギー作 用又は抗炎症作用等を有する成分が産生される場合があることが知られている。そし て、このような様々な機能を見出すことにより、その成分等を利用した、医薬、化粧料 、機能性飲食品等が種々開発され、市販されている。  [0002] Fermented milk fermented lactic acid bacteria metabolites such as whey, lactic acid bacteria extracellular or intracellular products have various functions useful for health depending on differences in the bacterial species fermentation conditions, etc. It has been found that there are cases. For example, a component having an intestinal regulating action, an antitumor action, an antihypertensive action, an antiallergic action or an anti-inflammatory action is produced in a specific fermentation metabolite, or in an extracellular product or an intracellular product. It is known that there are cases. And by discovering such various functions, various medicines, cosmetics, functional foods and drinks, etc. using the components have been developed and marketed.
また、近年、特定の乳酸菌発酵代謝物に、皮膚に対する有用な機能が見出されて いる。例えば、特許文献 1には、ストレプトコッカス属又はラタトコッカス属微生物を培 養した培養上清が、メラニン生成抑制作用を有すること、特許文献 2には、ラタトバチ ルス.ヘルべティカス MIKI-020(FERM P-13678)株の培養物又はその代謝産物と、グ ルコサミン及び/又は N—ァセチルダルコサミンとを併用した組成物力 メラニン産生 抑制作用及びコラーゲン産生促進作用を有することが記載されている。  In recent years, useful functions for skin have been found in certain fermented metabolites of lactic acid bacteria. For example, Patent Document 1 discloses that a culture supernatant obtained by culturing a microorganism belonging to the genus Streptococcus or Ratatococcus has a melanin production-inhibiting action, and Patent Document 2 includes Ratatobacillus helveticus MIKI-020 (FERM P -13678), a composition comprising a culture of a strain or a metabolite thereof together with glucosamine and / or N-acetyldarcosamine, which has a melanin production inhibitory effect and a collagen production promoting action.
[0003] ところで、近年のオゾン層の破壊等にともない、紫外線による皮膚への悪影響が問 題になっている。例えば、紫外線による、シミ、シヮ等の皮膚の老化、日焼けによる皮 膚の黒化、それに伴う皮膚癌の恐れ、紫外線の浴び過ぎによる皮膚の免疫機能の低 下等が問題になっている。  [0003] By the way, with the recent destruction of the ozone layer and the like, adverse effects on the skin due to ultraviolet rays have become a problem. For example, skin aging such as spots and wrinkles due to ultraviolet rays, skin blackening due to sunburn, the risk of skin cancer associated therewith, and deterioration of the immune function of the skin due to excessive exposure to ultraviolet rays have become problems.
[0004] しかし、これらの症状を改善する機序の解明は現状十分とは言えず、様々なファタ ターが考えられる他、個人における皮膚の色や水分量の相違、更には皮膚質や体 質等によってもその症状は異なるため、紫外線による皮膚への悪影響を改善する手 段も現状十分であるとは言い難い。このような手段としては、例えば、一般に日焼け 止めと称される、紫外線の皮膚への照射をブロックする外用剤、日焼け後の皮膚炎 症等を緩和する保湿剤や、該炎症を治療する薬剤、更には、チロシナーゼ阻害にか 力るメラニン産生抑制作用を有する美白剤等を用いる手段が主に行われているに過 ぎない。これらのほとんどは皮膚外用剤として使用した際に得られる作用を期待した ものである。 [0004] However, elucidation of the mechanism to improve these symptoms is not sufficient at present, and various fatters are conceivable, as well as differences in skin color and water content among individuals, as well as skin quality and constitution. Symptoms vary depending on the condition of the skin. It is hard to say that the stage is sufficient. Examples of such means include, for example, an external preparation that is generally referred to as sunscreen, which blocks irradiation of ultraviolet rays on the skin, a moisturizing agent that relieves dermatitis after sunburn, a drug that treats the inflammation, Furthermore, only a means using a whitening agent or the like having a melanin production-suppressing action capable of inhibiting tyrosinase is mainly used. Most of these are expected to have an effect when used as a topical skin preparation.
近年、皮膚の紫外線に対する感受性自体を改善しうる成分の探索及び提案も一部 なされて!/、るようであるが、ラクトバチルス ·ヘルべティカスの発酵乳ホエーを経口摂 取することによりそのような作用が得られることにつ ヽては知られて ヽな 、。  In recent years, there have been some searches and proposals for ingredients that can improve the skin's sensitivity to ultraviolet radiation itself! //, but by taking orally ingesting fermented milk whey of Lactobacillus helveticus It ’s known that you can get a good effect.
特許文献 1:特開平 4— 264016号公報  Patent Document 1: Japanese Patent Laid-Open No. 4-264016
特許文献 2 :特開 2002— 80340号公報  Patent Document 2: Japanese Patent Laid-Open No. 2002-80340
発明の開示  Disclosure of the invention
発明が解決しょうとする課題  Problems to be solved by the invention
[0005] 本発明の課題は、経口摂取により、紫外線による、皮膚紅斑発症抑制作用、該紅 斑に伴う皮膚黒化抑制作用等の皮膚における紫外線感受性抑制作用を有する剤及 び該剤を含む機能性飲食品を提供することにある。 [0005] An object of the present invention is to provide an agent having an action of inhibiting ultraviolet sensitivity in the skin, such as an action of suppressing the onset of skin erythema and an effect of suppressing skin darkening associated with the erythema, by ultraviolet radiation, and a function comprising the agent. To provide sex food and drink.
課題を解決するための手段  Means for solving the problem
[0006] 本発明によれば、ラクトバチルス ·ヘルべティカスにより乳を発酵させて得られる発 酵乳ホエーを有効成分として含む、経口摂取用の皮膚における紫外線感受性抑制 剤が提供される。  [0006] According to the present invention, there is provided an ultraviolet sensitivity inhibitor for skin for oral consumption, comprising fermented milk whey obtained by fermenting milk with Lactobacillus helveticus as an active ingredient.
また本発明によれば、前記皮膚における紫外線感受性抑制剤を含み、皮膚におけ る紫外線感受性抑制作用を有することを特徴とする機能性飲食品が提供される。 更に本発明によれば、経口摂取用の皮膚における紫外線感受性抑制剤を製造す るための、ラクトバチルス ·ヘルべティカスにより乳を発酵させて得られる発酵乳ホェ 一の使用が提供される。  In addition, according to the present invention, there is provided a functional food or drink comprising the ultraviolet sensitivity inhibitor in the skin and having an ultraviolet sensitivity inhibitory action in the skin. Furthermore, according to the present invention, there is provided use of a fermented milk whey obtained by fermenting milk with Lactobacillus helveticus for producing an ultraviolet sensitivity inhibitor in skin for oral intake.
発明の効果  The invention's effect
[0007] 本発明の皮膚における紫外線感受性抑制剤及び機能性飲食品は、既に経口摂取 によりその安全性が確認されている、ラクトバチルス 'ヘルべティカスにより乳を発酵さ せて得られる発酵乳ホエーを有効成分とするので、安全に、紫外線による、皮膚紅 斑発症抑制作用、該紅斑に伴う皮膚黒化抑制作用等の皮膚における紫外線感受性 抑制作用を得ることができ、長期による継続的摂取により、例えば、皮膚の紫外線に よる皮膚老化防止、特に、紫外線に対して敏感肌なヒト、光線過敏性皮膚疾患になり 易いヒト、紫外線による頭皮ダメージを受け易いヒト等における症状の発症を軽減若 しくは抑制し、更には、肌質改善効果等が期待できる。 [0007] The ultraviolet sensitivity inhibitor and functional food and drink in the skin of the present invention have already been orally ingested. The fermented milk whey obtained by fermenting milk with Lactobacillus helveticus has been confirmed as an active ingredient. Inhibition of UV sensitivity in the skin, such as skin darkening suppression effect associated with skin, and long-term continuous ingestion, for example, prevention of skin aging due to UV rays on the skin, especially humans sensitive to UV rays, It is possible to reduce or suppress the onset of symptoms in humans who are prone to photosensitivity skin diseases, humans who are susceptible to damage to the scalp due to ultraviolet rays, etc., and can also be expected to improve skin quality.
発明を実施するための最良の形態  BEST MODE FOR CARRYING OUT THE INVENTION
[0008] 以下、本発明を更に詳細に説明する。  [0008] Hereinafter, the present invention will be described in more detail.
本発明の皮膚における紫外線感受性抑制剤は、ラクトバチルス ·ヘルべティカス〖こ より乳を発酵させて得られる発酵乳ホエーを有効成分として含む、経口摂取用の剤 である。  The UV sensitivity inhibitor in the skin of the present invention is an agent for oral consumption containing fermented milk whey obtained by fermenting milk from Lactobacillus helveticus soy sauce as an active ingredient.
ラクトバチルス ·ヘルべティカスの菌株としては、菌体外プロティナーゼ活性の高!ヽ ものが好ましい。例えば、 Twiningらの方法 (Twining, S. Anal. Biochem. 143 3410(198 4))をもとにした Yamamotoらの方法 (Yamamoto, N.ら J.Biochem. (1993) 114, 740)に準 じて測定した UZOD590の値力 00以上を示す菌株が好ましい。また、下記の菌学 的性質を有するラクトバチルス 'ヘルべティカス菌株を用いることができる。  As a strain of Lactobacillus helveticus, a strain having a high extracellular proteinase activity is preferable. For example, based on the method of Yamamoto et al. (Yamamoto, N. et al. J. Biochem. (1993) 114, 740) based on the method of Twining et al. (Twining, S. Anal. Biochem. 143 3410 (198 4)). A strain having a UZOD590 value of 00 or more as measured above is preferred. In addition, Lactobacillus helveticus strains having the following mycological properties can be used.
[0009] 菌学的性質 [0009] Mycological properties
1.形態学的性質: 1)細胞の形状;桿菌、 2)運動性;なし、 3)胞子の有無;なし、 4)グ ラム染色性;陽性。  1. Morphological properties: 1) Cell shape; Neisseria gonorrhoeae; 2) Motility; None; 3) Presence of spores; None; 4) Gram staining;
2.生理学的性質: 1)カタラーゼ;陰性、 2)インドール生成;陰性、 3)硝酸塩の還元; 陰性、 4)酸素に対する態度;通性嫌気性菌、 5)グルコースによりホモ乳酸発酵により DL ( -)乳酸を生成し、ガスの産生はない。  2. Physiological properties: 1) Catalase; Negative, 2) Indole formation; Negative, 3) Reduction of nitrate; Negative, 4) Attitude toward oxygen; Facultative anaerobe, 5) DL (-by homolactic fermentation with glucose ) Lactic acid is produced, and no gas is produced.
6)各種炭水化物の分解性:グルコース; +、ラタトース; +、マンノース; +、フラクトー ス; +、ガラクトース; +、シユークロース; 、マノレトース; 、キシロース; 、ラムノー ス;一、セルビオース; 、トレハロース; 、メルビオース; 、ラフイノース; -、スタキ オース;一、マンニトール;一、ソルビトール;一、エスクリン;一、サリシン;一。  6) Degradability of various carbohydrates: glucose; +, ratatose; +, mannose; +, fructose; +, galactose; +, sucrose;, xylose; -, Raffinose;-, stachyose; 1, mannitol; 1, sorbitol; 1, esculin; 1, salicin;
[0010] 前記好ましいラクトバチルス ·ヘルべティカスとしては、例えば、ラクトバチルス 'ヘル ベティカス CM4株 (独立行政法人産業技術総合研究所特許生物寄託センター 日本 国茨城県つくば巿東 1 1 1中央第 6寄託番号: FERM BP— 6060,寄託日 199 7. 8. 15) (以下、 CM4株と称す)が挙げられる。この CM4株は、特許手続上の微生 物寄託の国際的承認に関するブタペスト条約に上記寄託番号で登録されており、こ の株は既に特許されている。 [0010] Examples of the preferred Lactobacillus helveticus include Lactobacillus Beticus CM4 strain (National Institute of Advanced Industrial Science and Technology, Patent Biological Depositary Center, Tsukuba Rokuto, Ibaraki, Japan 1 1 1 Central Deposit Number: FERM BP—6060, Deposit Date 199 7. 8. 15) (hereinafter CM4 (Referred to as stock). This CM4 strain has been registered with the above deposit number in the Budapest Treaty on the International Approval of Deposits of Microorganisms in Patent Proceedings, and this strain has already been patented.
[0011] 前記発酵乳ホェ一は、前記ラクトバチルス 'ヘルべティカスを含む発酵乳スターター を乳に添加し、発酵温度等の発酵条件を適宜選択して発酵させることにより得ること ができる。 [0011] The fermented milk whey can be obtained by adding the fermented milk starter containing the Lactobacillus helveticus to milk, and appropriately fermenting the fermentation conditions such as fermentation temperature.
有効成分である発酵乳ホェ一は、得られる発酵乳から遠心分離、ろ過等の常法の 分離操作によりホエーを分離することにより得られる。使用に際しては、分離せずに 発酵乳の状態で、また分離したホエーを適宜、分画、濃縮、精製等して用いることが できる他、該ホエーやその濃縮物を凍結乾燥、噴霧乾燥等により粉末として用いるこ とちでさる。  Fermented milk whey, which is an active ingredient, can be obtained by separating whey from the obtained fermented milk by conventional separation operations such as centrifugation and filtration. In use, in the state of fermented milk without separation, the separated whey can be used for fractionation, concentration, purification, etc. as appropriate, and the whey and its concentrate can be freeze-dried, spray-dried, etc. Use as a powder.
[0012] 前記ラクトバチルス ·ヘルべティカスは、あら力じめ前培養しておいた十分に活性の 高いスターターとして用いることが好ましい。初発菌数は、好ましくは 105〜109個/ m 1程度である。 [0012] The Lactobacillus helveticus is preferably used as a sufficiently active starter that has been pre-cultured. The initial bacterial count is preferably about 10 5 to 10 9 cells / m 1.
有効成分である前記特定の発酵乳ホェ一は、例えば、特定保健用食品等の機能 性飲食品に利用するに際して、風味を良好にし、嗜好性を良好とするために、前記ラ タトバチルス ·ヘルべティカスに酵母を併用して発酵させることもできる。酵母の菌種 は特に限定されないが、例えば、サッカロマイセス 'セレピシェ等のサッカロマイセス 属酵母等が好ましく挙げられる。酵母の含有割合は、その目的に応じて適宜選択す ることがでさる。  The specific fermented milk whey, which is an active ingredient, is used, for example, in order to improve the flavor and the palatability when used in functional foods and drinks such as food for specified health use. It is also possible to ferment ticus with yeast. The strain of yeast is not particularly limited, and preferred examples include yeast of the genus Saccharomyces such as Saccharomyces cerevisiae. The content ratio of yeast can be appropriately selected according to the purpose.
[0013] 原料の乳としては、例えば、牛乳、馬乳、羊乳、山羊乳等の動物乳、及び豆乳等の 植物乳、これらの加工乳である脱脂乳、還元乳、粉乳、コンデンスミルク等が挙げら れ、牛乳、豆乳、これらの加工乳が好ましぐ牛乳又はその加工乳が特に好ましい。 乳の固形分濃度は特に限定されないが、例えば、脱脂乳を用いる場合の無脂乳固 形分濃度は、通常 3〜15質量%程度であり、生産性的には 6〜15質量%が好ましい [0014] 前記発酵は、通常静置若しくは撹拌培養により、例えば、発酵温度 25〜45°C、好 ましくは 30〜45°C、発酵時間 3〜72時間、好ましくは 12〜36時間で、乳酸酸度が 1 . 5以上になった時点で発酵を停止する方法等により行なうことができる。 [0013] Examples of the raw milk include animal milk such as cow's milk, horse milk, sheep milk and goat milk, and plant milk such as soy milk, skim milk, reduced milk, powdered milk, condensed milk, etc., which are processed milks thereof. Milk, soy milk, milk that is preferable to these processed milk or processed milk thereof is particularly preferable. The solid content concentration of milk is not particularly limited. For example, when using skim milk, the solid content concentration of non-fat milk is usually about 3 to 15% by mass, and 6 to 15% by mass is preferable in terms of productivity. [0014] The fermentation is usually performed by standing or stirring culture, for example, fermentation temperature 25-45 ° C, preferably 30-45 ° C, fermentation time 3-72 hours, preferably 12-36 hours, It can be carried out by a method of stopping fermentation when the lactic acid acidity becomes 1.5 or more.
[0015] 本発明の皮膚における紫外線感受性抑制剤は、前記有効成分である発酵乳ホェ 一の他に、他の紫外線感受性抑制作用を有する成分等を含んでいても良ぐ更に、 その形態に応じては、賦形剤等の各種添加剤が含まれて!/ヽても良 、。 [0015] The ultraviolet-sensitivity inhibitor in the skin of the present invention may contain other components having an ultraviolet-sensitivity-inhibiting action in addition to the fermented milk whey as the active ingredient. Including various additives such as excipients! / It ’s okay.
本発明の皮膚における紫外線感受性抑制剤は、必須の有効成分が前記発酵乳ホ エーであるので、その経口摂取量は、摂取期間やその継続性等に応じて所望の効 果が得られるよう適宜選択できる。該摂取量は、通常、前記発酵乳ホエー量で、 1日 あたり 1〜: LOOOmlZヒト程度であり、好ましくは 10〜200mlZヒト程度である。  Since the essential active ingredient is the fermented milk whey, the ultraviolet sensitivity inhibitor in the skin of the present invention is appropriately adjusted so that the oral intake can have a desired effect depending on the intake period and its continuity. You can choose. The ingested amount is usually about 1 to: LOOOmlZ human, preferably about 10 to 200 mlZ human per day, as the fermented milk whey amount.
本発明の紫外線感受性抑制剤の摂取は、実質的に継続的に行うことが最も好まし いが、断続的であってもその断続的摂取を継続することでその効果が期待できる。伹 し、その効果発現は、通常、数週間〜数ケ月摂取後に顕著になることが多いので、例 えば、紫外線量が多くなる季節に備えて、その数週間〜数ケ月前から実質的に連続 的に摂取することが特に好ましい。  It is most preferable to take the UV sensitivity inhibitor of the present invention substantially continuously, but even if it is intermittent, the effect can be expected by continuing the intermittent intake. However, the manifestation of the effect is usually noticeable after ingestion for several weeks to several months.For example, in preparation for the season when the amount of ultraviolet rays increases, it is substantially continuous from several weeks to several months in advance. Is particularly preferred.
[0016] 本発明の機能性飲食品は、本発明の紫外線感受性抑制剤を含む。 [0016] The functional food or drink of the present invention contains the ultraviolet sensitivity inhibitor of the present invention.
本発明の機能性飲食品は、本発明の紫外線感受性抑制剤の他に、必要に応じて 、ラクトバチルス ·ヘルべティカス以外の乳酸菌の発酵物や、その他、飲食品に用い る他の成分、例えば、糖類、タンパク質、脂質、ビタミン、ミネラル、フレーバー、また はこれらの混合物等の添加物を含ませることもできる。また、本発明の紫外線感受性 抑制剤の有効成分である前記発酵乳ホエーを分離する前のホエー以外の乳成分を 更に含んでいても良い。更にまた、その形態に応じては、賦形剤等の各種添加剤が 含まれていても良い。  In addition to the ultraviolet sensitivity inhibitor of the present invention, the functional food or drink of the present invention, if necessary, a fermented product of lactic acid bacteria other than Lactobacillus helveticus, and other ingredients used for food and drink, For example, additives such as sugars, proteins, lipids, vitamins, minerals, flavors, or mixtures thereof may be included. Moreover, milk components other than whey before separating the fermented milk whey, which is an active ingredient of the ultraviolet sensitivity inhibitor of the present invention, may further be included. Furthermore, depending on the form, various additives such as excipients may be included.
本発明の機能性飲食品の摂取は、個人の皮膚における紫外線の感受性の相違、 季節や地域の違いによる紫外線照射量、該紫外線を浴びる量の相違等を勘案して、 実質的に継続的に行うことが最も好ましいが、断続的であってもその断続的摂取を継 続することでその効果が期待できる。但し、その効果発現は、通常、数週間〜数ケ月 摂取後に顕著になることが多いので、例えば、紫外線量が多くなる季節に備えて、そ の数週間〜数ケ月前力 実質的に連続的に摂取することが特に好ましい。 The intake of the functional food and drink of the present invention is substantially continuously in consideration of the difference in sensitivity to ultraviolet rays in the individual's skin, the amount of ultraviolet irradiation depending on the season and region, the difference in the amount of exposure to the ultraviolet rays, and the like. Although it is most preferable, even if it is intermittent, the effect can be expected by continuing the intermittent intake. However, the effects are usually prominent after ingestion for several weeks to several months. For example, in preparation for the season when the amount of ultraviolet rays increases, It is particularly preferable to take a substantially continuous force for several weeks to several months.
[0017] 本発明の機能性飲食品は、本発明の紫外線感受性抑制剤を含み、皮膚における 紫外線感受性抑制作用を有する食品及び飲料であって、紫外線による皮膚のダメー ジの予防や改善を訴求した、例えば、特定保健用食品等とすることができる。  [0017] The functional food and drink of the present invention are foods and beverages containing the ultraviolet sensitivity inhibitor of the present invention and having an ultraviolet sensitivity suppressing action on the skin, and appealed for prevention and improvement of skin damage caused by ultraviolet rays. For example, it may be a food for specified health use.
本発明の機能性飲食品において、本発明の紫外線感受性抑制剤の配合割合は、 飲食品の形態や種類に応じて適宜選択することができる。該配合割合は、その機能 性飲食品の摂取継続性等に応じて適宜選択することができ特に限定されないが、通 常、前記有効成分である発酵乳ホエー換算で 0. 1〜: LOO質量%、好ましくは 10〜9 0質量%の範囲が適当である。  In the functional food and drink of the present invention, the blending ratio of the ultraviolet sensitivity suppressor of the present invention can be appropriately selected according to the form and type of the food and drink. The blending ratio can be appropriately selected depending on the continuation of intake of the functional food and drink, and is not particularly limited, but is usually 0.1 to LOO% by mass in terms of fermented milk whey as the active ingredient. The range of 10 to 90% by mass is suitable.
前記機能性飲食品の形態としては、例えば、ヨーグルト、乳酸菌飲料等の発酵乳製 品、発酵乳ホエー又はその濃縮物等を配合した各種加工飲食品、乾燥粉末、錠剤、 カプセル剤、顆粒剤等が挙げられる。  Examples of the functional foods and drinks include, for example, fermented milk products such as yogurt and lactic acid bacteria beverages, various processed foods and drinks blended with fermented milk whey or concentrates thereof, dry powders, tablets, capsules, granules, etc. Is mentioned.
[0018] 本発明の紫外線感受性抑制剤及び機能性飲食品は、紫外線に対して敏感肌なヒ ト、光線過敏性皮膚疾患になり易いヒト、紫外線による頭皮ダメージを受け易いヒト等 に特に有効である力 このようなヒト以外でも、紫外線を多く浴びることにより、皮膚の 例えば免疫機能が突然若しくは徐々に低下する可能性があるので、そのような症状 が発症する以前から、毎日継続的に、又は毎日でなくともそれを継続して摂取するこ とが好ましい。  [0018] The ultraviolet sensitivity inhibitor and functional food and drink of the present invention are particularly effective for humans sensitive to ultraviolet rays, humans who are prone to photosensitivity skin diseases, humans who are easily damaged by scalp by ultraviolet rays, and the like. A force other than such humans, exposure to a lot of ultraviolet rays can cause sudden or gradual decline in, for example, the immune function of the skin, so every day before such symptoms develop, or It is preferable to take it continuously even if not every day.
実施例  Example
[0019] 以下、実施例を参照して本発明をより詳細に説明するが、本発明はこれらに限定さ れない。  Hereinafter, the present invention will be described in more detail with reference to examples, but the present invention is not limited thereto.
実施例 1  Example 1
(発酵乳ホエーの調製)  (Preparation of fermented milk whey)
固形率 9質量%脱脂粉乳力もなる乳培地に CM4株スターター (菌数 5 X 108個 ZmL )を 3%接種して、 37°Cで 24時間、静置状態で発酵させ発酵乳を得た。この発酵乳を 12000G、 20分間遠心分離し、沈殿を除去し、発酵乳ホエー (以下、発酵乳ホエー( A)という)を調製した。 Fermented milk was obtained by inoculating 3% CM4 strain starter (bacterial count 5 X 10 8 ZmL) in a milk medium with a solid content of 9% by weight nonfat dry milk and fermenting at 37 ° C for 24 hours. . This fermented milk was centrifuged at 12000 G for 20 minutes to remove the precipitate, and fermented milk whey (hereinafter referred to as fermented milk whey (A)) was prepared.
[0020] (発酵乳ホエー (A)含有飲料の調製) 上記調製した発酵乳ホエー (A)を飲用し易くするために、発酵乳ホエー (A)46. 65 質量部、香料 0. 2125質量部、アスパルテーム 0. 025質量部、水 49. 9048質量部 及び 50%乳酸 0. 7327質量部を混合し、発酵乳ホエー (A)含有飲料を調製した。 [0020] (Preparation of beverage containing fermented milk whey (A)) In order to make the prepared fermented milk whey (A) easy to drink, fermented milk whey (A) 46.65 parts by mass, flavoring 0.225 parts by mass, aspartame 0.025 parts by mass, water 49.9048 parts by mass and A beverage containing fermented milk whey (A) was prepared by mixing 0.7327 parts by mass of 50% lactic acid.
[0021] (最少紅斑量 (MED)評価) [0021] (Minimum erythema amount (MED) evaluation)
光源として Multiport Solar UV Simulator Model 601 (Solar Light Co. Inc.製、波長範 囲 290〜400nm、ピーク波長 356nm)を使用し、その照射強度は、多機能計測シス テムモデル PMA2100(Solar Light Co. Inc.製)を用い、被験部位を、日常生活で日 光曝露されにくい右上腕内側部とし測定を行った。照射量は、 0. 64、 0. 8、 1. 00、 1. 25、 1. 56及び 1. 95MEDとした。照射 24時間後に、各パネラーの最少紅斑量を 目視で判定した。  Multiport Solar UV Simulator Model 601 (manufactured by Solar Light Co. Inc., wavelength range 290 to 400 nm, peak wavelength 356 nm) is used as the light source, and its irradiation intensity is measured by the multifunctional measurement system model PMA2100 (Solar Light Co. Inc. And the test site was measured as the inner right upper arm that is difficult to be exposed to sunlight in daily life. The irradiation dose was 0.64, 0.8, 1.00, 1.25, 1.56 and 1.95 MED. After 24 hours of irradiation, the minimum amount of erythema for each panel was judged visually.
評価試験は、 24〜39歳の男性 22名をパネルとし、平均年齢 28. 8歳の、 11名及 び 11名の 2群に分け、まず、試料を飲用する前に実施し、各パネル群の平均値を求 めた。次いで、一方の群の各パネラーに発酵乳ホエー (A)含有飲料を 1日あたり 190 ml、他方の群の各パネラーに、発酵乳ホエー (A)含有飲料を飲用する代わりに水 19 0mlを毎日飲用してもらい、 9週間目に再度同様に紫外線照射を行い、最少紅斑量 を判定して、各群の平均値を求めた。結果を表 1に示す。  The evaluation test was conducted on 22 males aged 24 to 39 years as a panel, divided into two groups of 11 and 11 persons with an average age of 28. 8 years. The average value of was obtained. Next, each panel of one group received 190 ml of fermented milk whey (A) -containing drink per day, and each panel of the other group received 190 ml of water daily instead of drinking the fermented milk whey (A) -containing drink. In the 9th week, UV irradiation was performed again in the same manner, and the minimum amount of erythema was determined, and the average value of each group was determined. The results are shown in Table 1.
[0022] [表 1] [0022] [Table 1]
Figure imgf000008_0001
Figure imgf000008_0001
表 1の結果より、水飲用群では、 MEDがー 0. 13減少しているのに対して、発酵乳 ホエー (A)含有飲料の飲用群では、 MED力 . 11増加しており、発酵乳ホエー (A)含 有飲料を長期飲用することにより、紫外線による皮膚紅斑発症抑制作用が得られるこ とが半 IJつた。  Based on the results in Table 1, MED decreased by 0.13 in the drinking water group, whereas in the drinking group of fermented milk whey (A), the MED strength increased by 11. It was semi-IJ that long-term drinking of whey (A) -containing beverages can suppress the development of skin erythema caused by ultraviolet rays.
従って、発酵乳ホエー (A)含有飲料を継続飲用することにより、皮膚における紫外 線感受性抑制作用が得られ、紫外線による皮膚の老化等の抑制作用、更にはその ような皮膚への肌質改善が期待できる。 [0023] (紫外線による皮膚黒化抑制評価) Therefore, by continuing to drink the fermented milk whey (A) -containing beverage, it is possible to obtain an ultraviolet radiation sensitivity-inhibiting action in the skin, and to suppress the skin aging caused by ultraviolet rays, and to improve the skin quality of such skin. I can expect. [0023] (Skin darkening suppression evaluation by ultraviolet rays)
24〜39歳の男性 22名をパネルとし、平均年齢 28. 8歳の、 11名及び 11名の 2群 に分け、一方の群には、発酵乳ホヱー (A)含有飲料を 1日あたり 190mlを、他方の群 の各パネラーには、発酵乳ホエー (A)含有飲料を飲用する代わりに水 190mlを 9週 間飲用してもらった。  The panel consists of 22 men aged 24 to 39, divided into two groups of 11 and 11 people with an average age of 28. 8 years. One group is 190ml of fermented milk whey (A) -containing beverage per day. However, each panel of the other group was allowed to drink 190 ml of water for 9 weeks instead of drinking the fermented milk whey (A) -containing beverage.
6週目に、各パネルの、日常生活で日光曝露されにくい左上腕内側の皮膚色を、 分光測色計 (CM-2600d、ミノルタ社製)にて予め測定した。測定は 3回行い、その平 均値を皮膚色 (L *値)とした。次いで、光源として Multiport Solar UV Simulator Mode 1 601 (Solar Light Co. Inc.製、波長範囲 290〜400nm、ピーク波長 356nm)を使用し 、 1.5MEDに相当する紫外線を照射して、直径約 lcmの色素沈着を作成した。  On the 6th week, the skin color inside the left upper arm, which is not easily exposed to sunlight in daily life, was measured in advance with a spectrocolorimeter (CM-2600d, manufactured by Minolta). The measurement was performed three times, and the average value was defined as the skin color (L * value). Next, Multiport Solar UV Simulator Mode 1 601 (manufactured by Solar Light Co. Inc., wavelength range 290 to 400 nm, peak wavelength 356 nm) is used as a light source, and ultraviolet rays corresponding to 1.5 MED are irradiated to give a dye having a diameter of about lcm. Created a deposit.
次に、 7週目に上記で作成した色素沈着部位の皮膚色 (L *値)を同様に測定した。 6週目に測定した各群の平均皮膚色 (L *値)と、 7週目に測定した各群の平均皮膚 色 (L *値)との差を求めた。結果を表 2に示す。  Next, the skin color (L * value) of the pigmentation site prepared above was measured in the same manner on week 7. The difference between the average skin color (L * value) of each group measured at the 6th week and the average skin color (L * value) of each group measured at the 7th week was determined. The results are shown in Table 2.
また、各群のパネラーの皮膚表面水分量を測定し、各群のパネルから水分量の多 いパネラーを選抜し、これらのパネルの 6週目に測定した各群の平均皮膚色 (L *値) と、 7週目に測定した各群の平均皮膚色 (L *値)との差を求めた。具体的には、水摂 取群から 5名のパネラーを選抜し (これら 5名の平均皮膚表面水分量は、 42. 9)、発 酵乳ホエー (A)摂取群から 6名のパネラーを選抜して (これら 6名の平均皮膚表面水分 量は、 42. 7)、上記 L *値の差を求めた。結果を表 3に示す。  In addition, we measured the skin surface moisture content of each group's panelists, selected panelists with high moisture content from the panels of each group, and measured the average skin color (L * value) of each group measured at the 6th week of these panels. ) And the average skin color (L * value) of each group measured at the 7th week. Specifically, 5 panelists were selected from the water intake group (the average skin surface water content of these 5 persons was 42.9), and 6 panelists were selected from the fermented milk whey (A) intake group. (The average skin surface moisture content of these 6 people was 42.7), and the difference in L * value was calculated. The results are shown in Table 3.
[0024] [表 2]
Figure imgf000009_0001
[0024] [Table 2]
Figure imgf000009_0001
[0025] [表 3]  [0025] [Table 3]
Figure imgf000009_0002
Figure imgf000009_0002
表 2より、発酵乳ホエー (A)含有飲料を長期飲用することにより得られた、 L *値減少 量が水摂取よりも低いという結果から、皮膚の明度が明るい状態を維持でき、紫外線 照射によって生じる皮膚が黒化される割合が抑制されることが判った。また、パネル の皮膚表面水分量の平均を略一致させて比較した表 3の結果では、表 2の結果に比 ベ、発酵乳ホエー (A)含有飲料摂取群の上記 L *値減少量が著しく低力つたので、 略皮膚表面水分量を一致させて比較した場合、紫外線照射によって生じる皮膚が黒 化される割合が顕著に抑制されることが判った。 From Table 2, L * value reduction obtained by long-term drinking of fermented milk whey (A) -containing beverage From the result that the amount was lower than that of water intake, it was found that the brightness of the skin can be kept bright, and the ratio of skin darkening caused by ultraviolet irradiation is suppressed. In addition, in the results of Table 3 where the average of the skin surface moisture content of the panel was substantially matched, the L * value reduction amount of the drink intake group containing fermented milk whey (A) was significantly higher than the results of Table 2. It was found that the ratio of blackening of the skin caused by UV irradiation was remarkably suppressed when compared with the same amount of moisture on the skin surface.

Claims

請求の範囲 The scope of the claims
[1] ラクトバチルス ·ヘルべティカスにより乳を発酵させて得られる発酵乳ホエーを有効 成分として含む、経口摂取用の皮膚における紫外線感受性抑制剤。  [1] An ultraviolet-sensitivity inhibitor for skin for oral consumption, comprising fermented milk whey obtained by fermenting milk with Lactobacillus helveticus as an active ingredient.
[2] ラクトバチルス ·ヘルべティカスカ、ラクトバチルス ·ヘルべティカス CM4株 (独立行 政法人産業技術総合研究所特許生物寄託センター寄託番号: FERM BP 6060) である請求項 1記載の紫外線感受性抑制剤。  [2] The ultraviolet-sensitive inhibitor according to claim 1, which is Lactobacillus helveticaska, Lactobacillus helveticas CM4 strain (National Institute of Advanced Industrial Science and Technology, Patent Biological Deposit Center: FERM BP 6060) .
[3] 皮膚における紫外線感受性抑制が、紫外線による、皮膚紅斑発症抑制及び Z又 は該紅斑に伴う皮膚黒化抑制である請求項 1又は 2記載の紫外線感受性抑制剤。 [3] The ultraviolet sensitivity inhibitor according to claim 1 or 2, wherein the ultraviolet sensitivity suppression in the skin is suppression of skin erythema onset by ultraviolet rays and skin darkening accompanying Z or erythema.
[4] 請求項 1〜3のいずれか 1項記載の皮膚における紫外線感受性抑制剤を含み、皮 膚における紫外線感受性抑制作用を有することを特徴とする機能性飲食品。 [4] A functional food or drink comprising the ultraviolet sensitivity inhibitor for skin according to any one of claims 1 to 3 and having an ultraviolet sensitivity inhibitory effect on skin.
[5] 経口摂取用の皮膚における紫外線感受性抑制剤を製造するための、ラクトバチル ス.ヘルべティカスにより乳を発酵させて得られる発酵乳ホエーの使用。 [5] Use of fermented milk whey obtained by fermenting milk with Lactobacillus helveticus to produce an ultraviolet-sensitive inhibitor in skin for oral consumption.
PCT/JP2006/304453 2005-03-09 2006-03-08 Agent for suppressing uv sensitivity in skin and functional beverage and food WO2006095764A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007507144A JPWO2006095764A1 (en) 2005-03-09 2006-03-08 UV sensitivity suppressor for skin and functional food and drink

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005-064927 2005-03-09
JP2005064927 2005-03-09

Publications (1)

Publication Number Publication Date
WO2006095764A1 true WO2006095764A1 (en) 2006-09-14

Family

ID=36953358

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/304453 WO2006095764A1 (en) 2005-03-09 2006-03-08 Agent for suppressing uv sensitivity in skin and functional beverage and food

Country Status (3)

Country Link
JP (1) JPWO2006095764A1 (en)
TW (1) TW200642693A (en)
WO (1) WO2006095764A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010071132A1 (en) 2008-12-15 2010-06-24 カルピス株式会社 Peptide for inhibiting skin aging
WO2017164298A1 (en) * 2016-03-24 2017-09-28 株式会社 明治 Composition for inhibiting erythema, method of using same, method for preparing same, method for inhibiting erythema, and lactic acid bacteria product

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05194258A (en) * 1991-11-22 1993-08-03 Calpis Food Ind Co Ltd:The Inhibitor of melanin pigment synthesis
JPH05255389A (en) * 1992-02-18 1993-10-05 Calpis Food Ind Co Ltd:The Cyclopeptide compound
JPH0710740A (en) * 1993-04-26 1995-01-13 Meiji Milk Prod Co Ltd Melamine production-inhibiting agent
JPH1198978A (en) * 1997-09-26 1999-04-13 The Calpis Co Ltd Tripeptide high productive lactobacillus helveticus lactic acid bacterium
WO2000041572A1 (en) * 1999-01-11 2000-07-20 Calpis Co., Ltd. Process for producing fermented milk containing angiotensin converting enzyme inhibitory peptide and process for producing milk serum
WO2001019324A1 (en) * 1999-09-14 2001-03-22 Isao Horiuchi Cosmetics
JP2002080340A (en) * 2000-07-03 2002-03-19 Sanki Shoji Kk Cosmetological composition
JP2004501199A (en) * 2000-06-28 2004-01-15 セリカウサ ベーヴェー Use of a composition consisting of or comprising at least catabolic whey
WO2005063196A1 (en) * 2003-12-25 2005-07-14 Calpis Co., Ltd. Skin moisturizing agent for oral intake and functional foods and drinks

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05194258A (en) * 1991-11-22 1993-08-03 Calpis Food Ind Co Ltd:The Inhibitor of melanin pigment synthesis
JPH05255389A (en) * 1992-02-18 1993-10-05 Calpis Food Ind Co Ltd:The Cyclopeptide compound
JPH0710740A (en) * 1993-04-26 1995-01-13 Meiji Milk Prod Co Ltd Melamine production-inhibiting agent
JPH1198978A (en) * 1997-09-26 1999-04-13 The Calpis Co Ltd Tripeptide high productive lactobacillus helveticus lactic acid bacterium
WO2000041572A1 (en) * 1999-01-11 2000-07-20 Calpis Co., Ltd. Process for producing fermented milk containing angiotensin converting enzyme inhibitory peptide and process for producing milk serum
WO2001019324A1 (en) * 1999-09-14 2001-03-22 Isao Horiuchi Cosmetics
JP2004501199A (en) * 2000-06-28 2004-01-15 セリカウサ ベーヴェー Use of a composition consisting of or comprising at least catabolic whey
JP2002080340A (en) * 2000-07-03 2002-03-19 Sanki Shoji Kk Cosmetological composition
WO2005063196A1 (en) * 2003-12-25 2005-07-14 Calpis Co., Ltd. Skin moisturizing agent for oral intake and functional foods and drinks

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MASUYAMA A.: "Lactobasillus helveticus Hakkonyu no Hifu ni Taisuru Koka", FRAGRANCE JOURNAL, vol. 33, no. 10, 15 October 2005 (2005-10-15), pages 71 - 76, XP003004049 *
TSUBOI S. ET AL.: "Hakkonyu Whey Toyo ni yoru Rat Shoka Karadaju Melatonin Gosei eno Eikyo", NIPPON YAKUGAKUKAI NENKAI KOEN YOSHISHU, vol. 125, no. 3, 5 March 2005 (2005-03-05), pages 43, 30-0148, XP003004052 *
YOSHIMURA C. ET AL.: "Lactobasillus helveticus Hakko Sanbutsu no Hifu ni Taisuru Koka", NIPPON NOGEI KAGAKUKAI TAIKAI KOEN YOSHISHU, 5 March 2005 (2005-03-05), pages 116, 29EI76BETA, XP003004051 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010071132A1 (en) 2008-12-15 2010-06-24 カルピス株式会社 Peptide for inhibiting skin aging
US9067972B2 (en) 2008-12-15 2015-06-30 Calpis Co., Ltd. Skin aging-inhibiting peptide
WO2017164298A1 (en) * 2016-03-24 2017-09-28 株式会社 明治 Composition for inhibiting erythema, method of using same, method for preparing same, method for inhibiting erythema, and lactic acid bacteria product

Also Published As

Publication number Publication date
JPWO2006095764A1 (en) 2008-08-14
TW200642693A (en) 2006-12-16

Similar Documents

Publication Publication Date Title
JP5791009B2 (en) Lactic acid bacteria and food or drink using them
KR20180108504A (en) Fermented product of colostrum and a cosmetic composition using the same
US20160074443A1 (en) Nano-sized kimchi lactic acid bacteria
JP2010047504A (en) Atopic dermatitis mitigative
EP3564382B1 (en) Fermented product and production method therefor
JP2008179601A (en) Cosmetic composition containing bacterium of genus lactobacillus
KR101956867B1 (en) Lactobacillus rhamnosus CKDB009 having anti-obesity and cholesterol lowering effect and uses thereof
EP1902720B1 (en) Fermented milk whey for an oral use in improving symptoms of atopic dermatitis, xeroderma or psoriasis.
KR102543494B1 (en) Novel probiotics and use thereof
JP2021527414A (en) Composition for improving intestinal function containing a strain of Leuconostocaceae
KR102311097B1 (en) Aerobic fermented product of colostrum
JP4680571B2 (en) Moisturizer for ingestion
KR101341263B1 (en) Method for manufacturing fermented turmeric using a probiotic strain, Lactobacills johnsonii IDCC 9203
KR100435168B1 (en) Lactic acid beverage containing acid-resistant Lactobacillus fermentum JS
KR101992331B1 (en) Leuconostoc citreum WiKim0059 having skin whitening and skin moisturizing activities and composition for comprising the same
KR100773059B1 (en) Novel microorganism having deglycosylating ability, the probiotics containing the same and the process for preparing them
JP5531283B2 (en) Intestinal immunity regulator
WO2006095764A1 (en) Agent for suppressing uv sensitivity in skin and functional beverage and food
JP2007126399A (en) Composition for increasing glutathione
KR102434006B1 (en) Food composition containing lactobacillus with anti-obesity activity
US20210315808A1 (en) Bacillus subtilis containing composition for teatement of gastrointestinal irregulairty
KR20220109664A (en) Bacillus licheniformis having the effect of preventing or improving for skin inflammation and uses thereof
KR20220015574A (en) Health assistance food
Dash Review of scientific evidence for efficacy of Lactobacillus acidophilus DDS-1 as a probiotic strain

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2007507144

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06715373

Country of ref document: EP

Kind code of ref document: A1